Alport Syndrome is one of the most rapidly progressive forms of CKD3-6

Although Alport syndrome may not be considered one of the most severe types of CKD, the condition causes a much more rapid progression to end-stage kidney disease (ESKD) and organ failure.3-6

ADPKD=autosomal dominant polycystic kidney disease.
*Based on data collected from 4 different studies.
†Based on the historical average annual estimated glomerular filtration rate decrease among pediatric patients (n=16/23) enrolled in the CARDINAL trial.

Keep Alport syndrome from going undetected

The severity of Alport syndrome makes early detection critical. Considering Alport syndrome when patients present with declining glomerular filtration rate—particularly when accompanied by hematuria and/or a family history of CKD/AS—may help accurately identify the condition sooner.1,2,8-11

Confirming an Alport syndrome diagnosis sooner is possible with genetic testing

Look beneath the surface:
Progression

Watch this video to learn how the progression of Alport syndrome varies from patient to patient and how the condition can be monitored.

Highlight Alport syndrome by recognizing the following signs:

  • Persistent Hematuria
  • Underlying Inflammation
  • Reduced GFR
  • Family History of CKD or Alport Syndrome

Test your knowledge on
Alport Syndrome

Never miss an update

Ongoing research continues to reveal previously unknown information about Alport syndrome. Join our mailing list for periodic updates about the condition.

Genetic testing for Alport syndrome and several other rare forms of chronic kidney disease is more accessible than ever before. Find out the eligibility requirements for no-charge genetic testing through KIDNEYCODE.


1. Kashtan CE, Ding J, Garosi G, et al. Alport syndrome: a unified classification of genetic disorders of collagen IV a345: a position paper of the Alport Syndrome Classification Working Group. Kidney Int. 2018;93(5):1045-1051. 2. Savige J, Colville D, Rheault M, et al. Alport syndrome in women and girls. Clin J Am Soc Nephrol. 2016;11(9):1713-1720. 3. Perkovic V, Jardine MJ, Neal B, et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295-2306. 4. Wright JT Jr, Bakris G, Greene T, et al; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):2421-2431. 5. Torres VE, Chapman AB, Devuyst O, et al; REPRISE Trial Investigators. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377(20):1930-1942. 6. Chertow GM, Appel GB, Anderoli S, et al. Study design and baseline characteristics of the CARDINAL trial: a phase 3 study of bardoxolone methyl in patients with Alport syndrome. Am J Nephrol. 2021;52(3):180-189. 7. Nestor JG, Groopman EE, Gharavi AG. Towards precision nephrology: the opportunities and challenges of genomic medicine. J Nephrol. 2018;31(1):47-60. 8. Gross O, Kashtan CE, Rheault MN, et al. Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome. Nephrol Dial Transplant. 2017;32(6):916-924. 9. Groopman E, Goldstein D, Gharavi A. Diagnostic utility of exome sequencing for kidney disease. Reply. N Engl J Med. 2019;380(21):2080-2081. 10. Arora P. Chronic kidney disease. Medscape. Updated August 1, 2019. Accessed September 16, 2020. https://emedicine.medscape.com/article/238798-overview.
References: